Today's Date: October 4, 2023
Investments and Innovations Drive Expansion of Europe's Elderly Care Medical Devices Market   •   Cartamundi and Warner Bros. Discovery Global Consumer Products Unveil the DC “Selfie Moments” Limited-Edition Hybrid   •   CAMS Wins Ragan CSR, ESG and Diversity Awards   •   Illume Fertility Founder and Medical Director, Dr. Mark Leondires, Co-Authors the First All-Inclusive Guide to Donor Conception   •   Statement - Ministers Anandasangaree, Vandal, Hajdu, and Ien issue a statement of support on Sisters in Spirit Day and the Natio   •   HTeaO Kicks Off 'Round Up with the Ryan Palmer Foundation'   •   Vancouver International Airport Selects LAT Multilingual to Engage with Chinese Travellers   •   Patrick and Brittany Mahomes’ 15 and the Mahomies Foundation Establishes National Partnership With Boys & Girls Clubs   •   Six wheelchair tennis players nominated to Santiago 2023 Canadian Parapan Am Team   •   MERGE Acquires Zee Jay Digital to Orchestrate the Content Supply Chain for Superior CX   •   Get a Free Google Pixel 8 and Unleash its Full 5G Potential Only at T-Mobile, America’s 5G Leader   •   Avangrid Schedules Third Quarter 2023 Earnings Release and Conference Call   •   Grupo EULEN announces Angeles Campoy as the New Chief Executive Officer for USA   •   Indie Beauty and Wellness Brand LĀ SOL Collective Expands Product Line with HYDRATE Body Oil   •   FINRA Foundation Awards 2023 Ketchum Prize to Long-Time Financial Fraud Fighter Doug Shadel   •   Consumers Energy Continues Clean Energy Transition with Plans for Solar Project at Former Coal Plant Location   •   NAREB's 60-CITY, BLACK WEALTH TOUR BEGINS IN HOUSTON WITH A COMMUNITY WEALTH BUILDING DAY   •   Qwoted Launches Free Networking Tools for PR Industry   •   Global Clean Energy Reports Largest Camelina Acreage Worldwide   •   ACE Cash Express Supports Homes For Our Troops to Help Veterans Rebuild Their Lives
Bookmark and Share

Zephyr AI Demonstrates Predictive Value of Artificial Intelligence (AI) with RWD for Label Expansion with Approved 3rd Generatio

TYSONS, Va. , June 02 /Businesswire/ - Zephyr AI, Inc. (“Zephyr AI”), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment to improve patients’ lives announced today a poster presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.

Tremendous progress has been achieved in recent years towards understanding the molecular underpinnings of cancer and has ushered in an era of precision medicine. Today, actionable biomarkers inform rational design of novel drugs, repurposing of existing medications, or new combination therapies. However, less than 20% of cancer patients are currently benefiting from these targeted therapies. There is therefore an acute need for new methods to identify the expanded population of patients who could benefit from existing drugs and improve patient selection and design of clinical trials evaluating new or repurposed drugs.

Zephyr AI’s machine learning algorithms identify pharmacological sensitivities and genetic vulnerabilities that fall outside the current single nucleotide variants or proteins that are typically used to identify patients that would respond to targeted therapies. Zephyr AI’s algorithms generate interpretable drug response predictions from real-world data (RWD) which are then validated with proven models.

Leveraging Zephyr AI’s Vulnerability NetworkTM Methodology, the poster will highlight the use of Zephyr AI’s systems biology informed machine learning framework, along with RWD from multiple tumor types, to identify the common genetic vulnerabilities in patients treated with an approved 3rd generation EGFR inhibitor. Using their Vulnerability NetworkTM Methodology, Zephyr AI was able to identify which patients would respond, even though they didn’t have the EGFR mutations listed in the drug’s label.

“Our goal is to enable more cancer patients to receive the benefits of precision medicine, especially those groups that are unrepresented in previous clinical trials,” said Zephyr AI CEO David L. Morgan II.

The company believes that their machine learning technology could be used in the future for drug target discovery, preclinical experiment optimization, candidate selection, patient enrollment, and post market label updates. Zephyr AI will partner with pharmaceutical companies and clinicians to use its advanced analytics to clean and interpret their existing data as well as layer in additional RWD and evidence.

About Zephyr AI

Zephyr AI is a high-growth healthcare technology company committed to radically reshaping traditional approaches to precision medicine. Through partnerships and proprietary data, Zephyr AI is curating the world’s most comprehensive healthcare dataset and marrying it with cutting-edge artificial intelligence algorithms to generate novel, translatable insights to build tools and products that support patients and providers and fuel ongoing research. At Zephyr AI, our mission-focused team of world-class software engineers and biologists leverage big data and next-generation technology to derive transformational insights and build enduring partnerships that will revolutionize the treatment of cancer, diabetes, and other diseases. Visit us at and follow us on Twitter, Instagram and LinkedIn.

STORY TAGS: Conference, Product/Service, Virginia, Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Medical Devices, Software, Artificial Intelligence, Internet, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News